FEATURE ARTICLES
Transforming the quality culture should include the adoption of software quality engineering (SQE), but what is it, and how can it impact the quality of your products and processes?
- Here's What You Need To Know About The Access Consortium Pathway
- Is Charisma An API?
- Maximizing The Value Of An Internal Audit Program In Pharmaceutical Quality Operations
- 3 Ways To Deliver A Pharma 4.0 Facility
- How To Improve Sponsor–CMO Collaboration Around Digital Deviations
- Innovation, Growth (and Happiness) Projected for Pharma
- Global Implications Of Zero Tariffs On Indian Pharma Exports To China
PHARMA ONLINE WHITE PAPERS
-
Small Molecule API Production: Unveiling The Impact Of Fermentation
Technological developments have led to growth in the suitability of fermentation for a myriad of applications. Explore the impact of the evolution of synthetic biology and supporting technologies on modern fermentation practice.
-
A Scalable Single-Use Two-Step pDNA Purification Process3/6/2024
Evaluate the performance of a single-use two-step plasmid purification process, and see how it compares to the existing three-step purification method.
-
A Strategic Guide For Biotech And Biopharma Leaders5/15/2025
Securing drug approval is a complex, high-stakes process, and outdated review workflows hinder progress. Explore modern solutions that accelerate timelines without compromising compliance or quality.
-
Mitigating Early Development Risks9/11/2024
Discover how the efficient screening of biologic candidates accelerates the discovery process, reduces costs, and improves the likelihood of commercializing safe and effective drugs.
-
Three Key Actions To Minimize Dead Volumes10/10/2025
Minimizing liquid dead volume helps labs conserve costly reagents and scarce samples while boosting assay throughput. Learn how advanced liquid level detection technologies are driving efficiency.
-
Stopper Migration In Frozen Pre-Filled Syringes10/16/2024
Review a semi-automated method for dynamically assessing plunger migration under controlled variations in temperature and pressure, utilizing computer vision tools.
PHARMA ONLINE APP NOTES & CASE STUDIES
NEWSLETTER ARCHIVE
- 11.29.25 -- Modernize Your Pharma Operations With Advanced Software Solutions
- 11.25.25 -- Considerations In Sterility Testing And Assurance
- 11.24.25 -- Your trusted filters made closer to you – try by yourself!
- 11.21.25 -- Leaders In The Excipient Market: Region And Type
- 11.20.25 -- Optimize Formulation And Integrity Workflows
INDUSTRY NEWS
-
9 Drugs Granted Fast Track By FDA's Voucher Program
With targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.
-
Leaders In The Excipient Market: Region And Type
Though North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.
-
Pfizer Strengthens Obesity Foothold With Metsera Acquisition
After discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
-
FDA Cracks Down On GLP-1 Imports
GLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
-
Oregon Court Upholds Drug Price Transparency Law
The law was first enacted in 2018, followed by a lawsuit by Pharmaceutical Research and Manufacturers of America (PhRMA) in 2019, claiming an infringement of free speech for pharmaceutical companies and violation of public property. PhRMA asked the court to bar Oregon from enforcing the law.
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
Explore how sterility assurance, including sterilization validation and environmental monitoring, is essential for controlling microbial contamination in mammalian cell production to ensure patient safety. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Large-Capacity Double Planetary Mixer Ideal For Highly Viscous Materials11/26/2025
ROSS recently completed the largest Double Planetary Mixer in its US history, a Model DPM-750 capable of mixing up to an impressive 750 gallons per batch and engineered with safety features for a Class I, Division 1, Group D hazardous environment. This heavy-duty mixer delivers the robust agitation required for ultra-high viscosity materials while adhering to demanding safety standards.
-
CSL To Build Out U.S. Plasma Capabilities Through $1.5B Investment11/24/2025
Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced plans to expand its U.S. presence over the next five years, resulting in approximately US$1.5b in U.S. capital investments. These investments will generate hundreds of high-quality American jobs, strengthen U.S. manufacturing capabilities of plasma-derived therapies (PDTs), and help secure the U.S. medicine supply chain. This reflects CSL’s commitment to meet the growing clinical need for immunoglobulin (Ig) over the long term.
-
Equipment Auction Announced For Sutro Biopharma Assets11/24/2025
December 15-16, 2025: Featuring late-model lab, R&D and manufacturing equipment surplus to future needs of Sutro BioPharma: spray dryer, chromatography systems, Westfalia seperators, HPLC’s & more.
-
Syntegon Delivers Strong Growth And Margin Expansion In Q3 2025 With Accelerating Pharma Momentum And Profitability Gains Across All Segments11/21/2025
Syntegon Group, a leading strategic partner to the pharmaceutical, biotech, and food industries, continued its strong growth and margin-improvement momentum in the third quarter of 2025, building on a successful first half of the year.
-
Novartis To Add Small Molecule & Fill/Finish Capacity With North Carolina Drug Manufacturing Investments11/20/2025
Novartis Gene Therapies, a division of Switzerland-based Novartis, one of the world’s largest pharmaceutical companies, plans to expand in the Research Triangle with $771 million of investments at multiple locations, creating its first biologics drug substance facility in the United States and adding small molecule manufacturing and new fill/finish capabilities.